Breast cancer clinical trials

Our researchers are conducting a number of clinical trials for breast cancer at the Kinghorn Cancer Centre. The current trials are looking for patients with early, advanced-stage breast cancer and patients that are undergoing breast cancer surgery. 

All trials are held at The Kinghorn Cancer Centre, Darlinghurst NSW.

Last updated: 23/6/2020

Contact us for further information, to see if you're eligible for treatment, or to enquire about an upcoming trial.

Claire Gray 
Email: claire.gray@svha.org.au
Phone: 02 9355 5617
Fax: 02 9355 5735

 

Early stage breast cancer

WinPro window study with prometrium (ER+/PR+)

A study of endocrine therapy with progesterone in post-menopausal women with early-stage hormone receptor positive breast cancer, prior to undergoing breast surgery.

Requirements: post-menopausal women with early-stage breast cancer which is estrogen and progesterone receptors positive, HER2 receptor negative, a tumour size of ≥1cm and have not yet had breast surgery.

Reference: HREC/17/SVH/255

GO40987 window study with GDC-9545 (ER+)

A study of endocrine therapy with GDC-9545 (selective oestrogen receptor degrader) in post-menopausal women with early-stage hormone receptor positive breast cancer, prior to undergoing breast surgery.

Requirements: post-menopausal women with early-stage breast cancer which is estrogen receptor positive, HER2 receptor negative, a tumour size of ≥1cm and have not yet had breast surgery.

Reference: HREC/2019/ETH00224

WO42133 neoadjuvant study with GDC-9545 (ER+)

A randomised study of endocrine therapy with GDC-9545 (selective oestrogen receptor degrader) and palbociclib (CDK4/6 inhibitor) versus anastrozole and palbociclib in post-menopausal women with early-stage hormone receptor positive breast cancer, prior to undergoing breast surgery.

Requirements: post-menopausal women with early-stage breast cancer which is estrogen receptor positive, HER2 receptor negative, a tumour size of ≥2cm and have not yet had breast surgery.

Reference: TBC – opening soon

Exercise during chemotherapy (all)

A study of exercise during chemotherapy for breast cancer given prior to surgery (neoadjuvant or preoperative chemotherapy). We will provide patients with a personalised exercise program and study the effects of exercise on the tumour at the time of surgery.

Requirements: patients with early-stage breast cancer who have their chemotherapy prior to surgery.

Reference: HREC/16/SVH/334

Read more

Advanced stage breast cancer

BO41843 with GDC-9545 (ER+)

A randomised study of novel oral selective oestrogen receptor degrader GDC-9545 and palbociclib versus letrozole and palbociclib for advanced ER+ breast cancer.

Requirements: patients with advanced breast cancer which is oestrogen receptor positive and HER2 receptor negative, and have not received prior treatment for metastatic disease.

Reference: TBC – opening soon

C-BOBCAT imaging study with Cu64-bombesin (ER+ PR+)

A study of novel Cu64-SAR-bombesin PET in advanced breast cancer embarking on new line of treatment.

Requirements: patients with advanced breast cancer, which is oestrogen receptor positive, progesterone receptor positive, and HER2 receptor negative.

Reference: TBC – opening soon

CAPTURE with alpelisib and fulvestrant (ER+)

A randomised study of oral PI3K inhibitor alpelisib with fulvestrant versus capecitabine for advanced ER+ breast cancer with PIK3CA mutation found on circulating tumour DNA test.

Requirements: patients with advanced breast cancer, which is oestrogen receptor positive and HER2 receptor negative, and has PIK3CA mutation as above; up to 2 prior lines endocrine therapy and 1 prior line of chemotherapy allowed.

Reference: TBC – opening soon

WO42312 with GDC-9545 (ER+)

A randomised study of oral selective oestrogen receptor degrader GDC-9545 versus physician’s choice endocrine therapy for advanced ER+ breast cancer.

Requirements: patients with advanced breast cancer which is oestrogen receptor positive and HER2 receptor negative, up to 2 prior lines allowed (including CDK4/6 inhibitor and/r up to 1 line chemotherapy).

Reference: TBC – opening soon

Destiny-Breast06 (ER+ HER2 low or IHC>0 <1+)

A randomised study of HER2 antibody-drug conjugate trastuzumab deruxtecan versus physician’s choice chemotherapy in advanced breast cancer.

Requirements: patients with advanced breast cancer which is oestrogen receptor positive and HER2 receptor low or IHC>0 <1+; up to 2 prior lines of endocrine therapy allowed; no prior chemotherapy permitted.

Reference: TBC – opening soon

PATINA study with palbociclib (ER+ HER2+)

A study of palbociclib (Ibrance) with trastuzumab (Herceptin), pertuzumab (Perjeta) and endocrine therapy for patients with advanced breast cancer.

Requirements: patients with advanced breast cancer which is estrogen and HER2 receptors positive, and have not received prior treatment for metastatic disease.

Reference: HREC/17/SVH/141

Read more

All patients undergoing breast surgery at St Vincent's Hospital

Project SHARE (Specimens Help All Research Efforts)

We invite all patients undergoing breast surgery at St Vincent’s Hospital to partner with us in our research endeavours. Tissue that is routinely collected at the time of surgery and in excess of diagnostic requirements will be brought to the laboratories at the Garvan Institute, enabling many researchers use these tissues as building blocks for their research.